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6/j.bInosine monophosphate dehydrogenase (IMPDH) is the target enzyme of mycophenolate mofetil (MMF).
Single nucleotide polymorphisms (SNPs) in the IMPDH1 gene are reportedly relevant to acute rejection
in renal transplant patients receiving MMF. The objective of this study was to identify the impact of IMPDH1
gene polymorphisms on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Four IMPDH1 gene SNPs (IVS7 1125 G.A, IVS8-106 G.A, exon15 1572 G.A, and 50 flanking intron-
exon region C.T) were analyzed in 240 consecutive pairs of transplant recipients and their donors. The
presence of the IMPDH1 IVS82106 G/G genotype in recipients was associated with a significantly higher
incidence of acute graft-versus-host disease (aGVHD) than other genotypes, in both unrelated and sibling
transplantation cohorts (unrelated cohort: 83.3% vs 63.9%, P 5 .048; sibling cohort: 47.6% vs 17.3%,
P 5 .008). Multivariate analysis confirmed that recipients with the IVS82106 G/G genotype were at
significantly higher risk of developing aGVHD (relative risk [RR] 5 2.018, 95% confidence interval [CI]:
1.354-3.009, P 5 .001) and grades II-IV aGVHD (RR 5 2.232, 95% CI: 1.352-3.685, P 5 .002). There was
no association among IVS7 1125, exon15 1572, and 50 flanking intron-exon region genotypes and the risk
of aGVHD. These results represent the first report of an association between IMPDH1 gene polymorphisms
and the risk of aGVHD in allo-HSCT.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is an established curative option for a
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bmt.2011.06.014diseases. The growing indications for allo-HSCT and
improvements in supportive care and conditioning reg-
imens have led to an increased number of allo-HSCT.
However, graft-versus-host disease (GVHD) remains
one of the most challenging obstacles to successful
allo-HSCT, and it limits the use of this important
procedure. The incidence of acute GVHD (aGVHD)
ranges from 35% to 45% in recipients after HLA fully
matched sibling transplantation, to 60% to 80% in
recipients after one-antigen HLA-mismatched, unre-
lated donor transplantation [1]. Acute GVHD can be
fatal in 15% to 40% of cases [2]. Recent evidence
suggests that polymorphisms in donor and recipient
non-HLA genes, including cytokine genes, innate im-
munity genes, and pharmacogenetic polymorphisms,
are associated with the risk of GVHD [3-7].
Mycophenolate mofetil (MMF) has been widely
used in organ transplantation and allo-HSCT. Inosine
monophosphate dehydrogenase (IMPDH) is the tar-
get enzyme of mycophenolic acid (MPA), the active
metabolite of MMF [8]. It is the key enzyme in
the de novo synthesis of guanosine nucleotides, and273
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in this process. T- and B-lymphocyte proliferation
critically depends on the IMPDH-driven pathway,
whereas other cell types have a salvage pathway for
the synthesis of guanosine nucleotides; MPA thus spe-
cifically inhibits the proliferation of these lymphocytes
[9]. There are 2 isoforms of IMPDH; IMPDH1 is
constructively expressed in all cell types, whereas
IMPDH2 is only expressed in particular cell types. In-
terindividual variability in IMPDH activity has been
observed among healthy volunteers, as well as among
transplant patients [10,11], leading to the speculation
that genetic variation within the IMPDH gene or in
its expression could at least partly explain the
variability in IMPDH activity and MMF response.
Single nucleotide polymorphisms (SNPs) of the
IMPDH1 and IMPDH2 genes are reportedly
relevant to acute rejection in renal transplant patients
receiving MMF [12-14]. However, there is no
evidence regarding the impact of IMPDH gene
polymorphisms on the outcomes of allo-HSCT. Al-
though IMPDH2 is 4.8 times more sensitive to MPA
inhibition than IMPDH1, IMPDH2 has low genetic
diversity [15]. Frequencies of the variant alleles in the
IMPDH2 gene that reportedly affect the outcomes
in renal transplant patients are very low in the Chinese
population, according to data referenced in the Gen-
Bank NCBI SNP databases. We therefore selected
4 candidate SNPs in the exons, the flanking intron-
exon regions, and the proximal promoter region of
the IMPDH1 gene, which have relatively high allele
frequencies in the Chinese population. To the best
of our knowledge, the present study is the first toTable 1. Patients, Disease, and Transplantation Characteristics in
Characteristics Unrelated Transplant (n 5 13
Age (median, range), years 24 (10–50)
Donor-recipient gender, n (%)
Female to male 35 (25.4)
Other 103 (74.6)
Reason for transplantation, n (%)*
Nonmalignant disease 6 (4.3)
Standard-risk cancer 117 (84.8)
High-risk cancer 15 (10.9)
Transplant material, n (%)
Bone marrow 56 (40.6)
Peripheral blood stem cells 82 (59.4)
Graft (media, range)
TNC count (108/kg) 6.05 (2.09–21.4)
CD34+ cell count (106/kg) 6.94 (0.9–30.7)
HLA matching
Allele matched 96 (69.6)
Allele mismatched (1–2 alleles) 42 (30.4)
Conditioning regimen, n (%)
Myeloablative 120 (87)
RIC 18 (13.0)
RIC indicates reduced-intensity conditionings; TNC, total nucleated cell.
*Nonmalignant diseases included aplastic anemia, myelodysplastic syndrome, an
lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and non
myelogenous leukemia (CML) in chronic phase. High-risk cancers included AL
myeloma, and Hodgkin’s disease.report on the association between IMPDH1 genetic
variants and the risk of GVHD in allo-HSCT.MATERIALS AND METHODS
Characteristics of the HSCT Patient Group
IMPDH1 genotyping was performed in 240 con-
secutive pairs of transplant recipients and their donors
who underwent allo-HSCT in our Bone Marrow
Transplantation Center from January 2001 to March
2009. The subjects were divided into 2 separate
cohorts: 1 cohort consisted of 138 pairs of recipients
and their unrelated donors (URDs), and the second
cohort included 102 pairs of recipients and their
HLA-identical sibling donors. There were no signifi-
cant differences between the 2 groups in terms of
donor-recipient gender, disease status before trans-
plantation, total nucleated cell count harvested in
graft, or conditioning regimen. However, there were
significant differences between the 2 groups in terms
of patient age, transplant material, and the status of
HLA allele matching (Table 1). The final analysis of
the clinical end points included both cohorts.
Low-resolution HLA typing had been performed
for HLA-A, -B, and -DRB1 in the sibling transplan-
tation group, and high-resolution DNA typing for
HLA-A, -B, -C, -DRB1, and -DQB1 in theURD trans-
plantation group.Themainmyeloablative conditioning
regimen used involved busulfan/cyclophosphamide
(BuCy) without total body irradiation (TBI); reduced-
intensity conditioning (RIC) regimens were predomi-
nantly fludarabine-based combinations without TBI.the First and Second Cohorts
8) Sibling Transplant (n 5 102) P Value
32 (14–52) <.001
33 (32.4) .249
69 (67.6)
6 (5.9) .766
90 (88.2) .57
6 (5.9) .248
12 (12.8) <.001
90 (87.2)
6.395 (0.89–23.4) .684
4.96 (0.715–16.6) .002
102 (100%) <.001
0
89 (87.3) .946
13 (12.7)
d paroxysmal nocturnal hematuria. Standard-risk cancers included acute
-Hodgkin lymphoma (NHL) in complete remission (CR) and chronic
L, AML, and NHL in relapse; CML in other than chronic phase; multiple
Biol Blood Marrow Transplant 18:273-279, 2012 275IMPDH1 Gene Polymorphisms and aGVHDAccording to clinical data and animal studies, MMF as
an adjunct to the combination of cyclosporine A (CSA)
and methotrexate (MTX) appeared to augment the
actions of standard immunosuppressant agents without
adding overlapping toxicities [16-23]. In our center,
recipients in both the unrelated and sibling trans-
plantation cohorts received the same GVHD
prophylaxis, consisting of CSA, MTX, and low-dose,
short-termMMF.CSAwas scheduled to be given intra-
venously at 2.5 mg/kg/day from day 21, with a target
blood level of 200 to 300 ng/mL. The dosage was
tapered during the second month posttransplantation,
according to chimeric status and evidence of GVHD.
MMF was initiated orally at 500 mg/day on day 11,
and withdrawn on day 1100. MTX was given at
10 mg/day on days 11, 13, and 16.
All the patients and their donors were of Chinese
origin. The study was approved by the local ethics
committee. All the patients and donors gave their
written informed consent.
DNA Extraction
Genomic DNA was extracted from peripheral
blood samples obtained from recipients and donors
before transplantation, using a salting-out method
with a commercial DNA extraction kit (Dynal Biotech,
Brown Deer, WI) and following the manufacturer’s
recommendations. DNA was quantified by spectro-
photometry.
Analysis of IMPDH1 Polymorphisms
Four SNPs in the IMPDH1 gene, including 2
intronic SNPs (IVS7 1125 G.A, rs2278293;
IVS82106 G.A, rs2278294), an exonic SNP
(Exon15 1572 G.A, rs2228075), and a 50 flanking
intron-exon region C.T (rs714510) were deter-
mined by multiplex SNaPshot technology, according
to previously described methods [24-26], using an
ABI fluorescence-based assay allelic discrimination
method (Applied Biosystems, Foster City, CA).
The primers for polymerase chain reaction (PCR)
amplification and SNaPshot extension reactions were
both designed to be aligned with the NCBI sequence
databases using Primer3 software. The extension
primer was designed to anneal immediately adjacentTable 2. Primers Sequences Used in the SNaPshot Reaction
Mutation Position* PCR Amplification Primers
IVS7 +125 G>A† (rs2278293) F TCCCTGCGTGTCCTTCCTCTC
R CCGTGATGAAGCCCTGTTCAAIVS8 2106 G>A (rs2278294)
Exon15 1572 G>A (rs2228075) F ACGCAGCGAGGGGGATAAAGT
R CACCCCCAGTCTCAGCACTCA
50 flanking intronexon region
C>T (rs714510)
F CCCTTTGAACCACTCACGCTCT
R CCCAGGGGATGGTTGAAGATG
*The position is relative to ATG start site with A as nucleotide +1 and based
†Designation of genetic variations: IVS7 +125 G>A denotes the G to A substto the nucleotide at the mutation site, on either the
sense or anti-sense DNA strand (Table 2).
PCR was performed in a total volume of 10 mL
containing 50 ng genomic DNA, 0.1 mM of each
primer, 0.3 mM each of dATP, dCTP, dTTP, and
dGTP, 1 unit of HotStarTaq polymerase (Qiagen
Inc., Chatsworth, CA), 4 mL of 1  buffer, and
3.0 mM MgCl2. The samples were put through 30 to
40 cycles of denaturation at 94C, annealing at specific
primer temperatures, elongation at 72C, and a final
extension at 72C. PCR product amplification was ver-
ified by running 5 mL of product on a 2% agarose gel.
The remaining product was then processed according
to the ABI SNaPshot protocol, using primers designed
for fluorescence dideoxynucleotide termination. SNP
analysis was performed using an ABI3130 genetic
analyzer. Genotypes were determined automatically
using Genemapper4.0 software (Applied Biosystems,
Bedford,MA). Genotyping was confirmed by sequenc-
ing 10% of randomly selected samples, as a quality
control measure.
Statistical Analysis
Only patients with successful engraftment and
who survived for more than 30 days were included
in the analysis of aGVHD. Acute GVHD was diag-
nosed and graded using established criteria [27].
Patients who survived $100 days were analyzed
for chronic GVHD (cGVHD), which was assessed
by National Institutes of Health (NIH) consensus
criteria [28]. Univariate analyses of the distribution
of IMPDH1 genotypes in patients with and with-
out aGVHD and cGVHD were performed using
Fisher exact tests. The cumulative incidents of
relapse, death in remission, and survival were esti-
mated using the Kaplan-Meier method, and the
generalized Wilcoxon test was used to analyze the
differences. The Cox proportional hazard model
was applied to multivariate analysis of the effects
of these characteristics on HSCT outcome. Statisti-
cal analysis was performed using SPSS software
version 16.0 (SPSS, Inc., Chicago, IL). All probabil-
ity values were 2-sided. P \ .05 was considered
statistically significant, and values of P between .05
and .1 were considered indicative of a trend.Extension Primers
F TTTTGCGTGTCCTTCCTCTCAGT
R GCTGCAGAGAAGCCAGGA
F TTTTTTTTTTTTTTTTTTTTTTTGGGGGATAAAGTGAAGATCGC
F TTTTTTTTTTTTTTTTTTTTTTGAAACCATGTTTTGATCCATCC
on mRNA sequence from GeneBank accession number NM_000884.
itution at nucleotide +125 of intron 7.
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IMPDH1 Allele Frequencies
The frequencies of IMPDH1 genotypes in recipi-
ents and donors were similar, and were also similar to
those referenced in the GenBank NCBI SNP data-
bases. There were no significant differences in the
distribution of IMPDH1 genotypes between the
URD and sibling transplantation cohorts (Table 3).
No significant deviations from the expected Hardy-
Weinberg genotype frequencies were observed in
either donors or recipients (data not shown).
Transplant Outcomes According to IMPDH1
Genotype
Analysis of the outcomes of the 2 separate cohorts
in the present study demonstrated a higher incidence
of aGVHD (68.1% vs 23.5%, P \ .001), severe
aGVHD (10.9% vs 1%, P 5 .004), and nonrelapse
mortality (NRM) (24.6% vs 9.8%, P 5 .004) in the
URD transplantation cohort, compared with the sib-
ling transplantation cohort. The cumulative overall
survival (OS) was higher in the sibling transplantation
cohort (74.5% vs 58%, P 5 .009). However, the inci-
dents of limited and extensive cGVHDwere compara-
ble in the URD and sibling transplantation cohorts
(16.7% vs 22.5%, P5 .31; 15.9% vs 10.8%, P5 .343,
respectively). There was no significant difference in
the cumulative incidence of relapse between the 2 co-
horts (21.0% vs 19.6%, P 5 .872).
The IMPDH1 IVS8-106 G/G genotype in recipi-
ents was significantly associated with a higher inci-
dence of aGVHD than other genotypes, in both the
unrelated and the sibling transplantation cohorts
(unrelated cohort: 83.3% vs 63.9%, P 5 .048; sibling
cohort: 47.6% vs 17.3%, P 5 .008). Furthermore,Table 3. Distribution of IMPDH1 Genotypes in the Donors and Re
Genotype
Donor Type
Unrelated
Cohort n (%)
Sibling
Cohort n (
IVS7 +125 (rs2278293)
G/G 47 (34.1) 36 (35.3)
G/A 64 (46.3) 49 (48.0)
A/A 27 (19.6) 17 (16.7)
IVS82106 (rs2278294)
G/G 35 (25.4) 25 (24.5)
G/A 61 (44.2) 42 (41.2)
A/A 42 (30.4) 35 (34.3)
Exon15 1572 (rs2228075)
G/G 62 (44.9) 45 (44.1)
G/A 53 (38.4) 41 (40.2)
A/A 23 (16.7) 16 (15.7)
50 flanking intron-exon region (rs714510)
C/C 89 (64.5) 65 (63.7)
T/C 39 (28.3) 31 (30.4)
T/T 10 (7.2) 6 (5.9)
The differences of the distribution of IMPDH1 genotypes in the first unrelated
performed using Fisher exact tests.the IMPDH1 IVS82106 G/G genotype in recipients
in the unrelated transplantation cohort was also
associated with a higher incidence of grades II-IV
aGVHD (63.3% vs 38.0%, P5 .021). However, donor
IMPDH1 IVS82106 genotype had no significant
impact on the incidence of aGVHD. There was no
association among IVS7 1125, exon15 1572, and 50
flanking intron-exon region genotypes and the risk of
aGVHD (Table 4).
However, the frequencies of all the IMPDH1
alleles were similar in patients with and without
cGVHD (data not shown), indicating no association
between cGVHD and IMPDH1 polymorphisms in
either recipients or donors.
Kaplan-Meier analysis found no significant associ-
ations between donor or recipient IMPDH1 genetic
variations and the cumulative incidents of relapse,
relapse-free survival, or OS after transplantation. Mul-
tivariate analysis to investigate the impact of IMPDH1
gene polymorphisms on survival was therefore not
undertaken.
Multivariate Analysis
IMPDH1 IVS82106 polymorphisms, together with
other clinical and biologic factors known to contribute to
the development of aGVHD, were subjected to multi-
variate Cox proportional hazard model analysis for
aGVHD. The following factors were analyzed: sibling
donor versus URD, transplant material (peripheral
blood stem cells versus bone marrow), donor-recipient
gender relation (male recipient/female donor, or other),
HLA matching, and conditioning regimen (myelo-
ablative conditioning vs RIC). The results are given in
Table 5. In the combined cohort, multivariate analysis
confirmed that recipients with the IMPDH1 IVS82106
G/G genotype were at significantly increased risk ofcipients in the Unrelated and Sibling Transplantation Cohorts
Recipient Type
%) P Value
Unrelated
Cohort n (%)
Sibling
Cohort n (%) P Value
.848 45 (32.6) 36 (35.3) .838
73 (52.8) 50 (49.0)
20 (14.5) 16 (15.7)
.812 28 (20.2) 23 (22.5) .156
76 (55.1) 44 (43.1)
34 (24.6) 35 (34.3)
.955 60 (43.5) 43 (42.2) .428
64 (46.4) 43 (42.2)
14 (10.1) 16 (15.7)
.878 77 (55.8) 62 (60.8) .376
54 (39.1) 32 (31.4)
7 (5.0) 8 (7.8)
transplantation cohort and second sibling transplantation cohort were
Table 4. Univariate Analyses of aGVHD and IMPDH1 Gene Polymorphisms in the Unrelated and Sibling Transplantation Cohorts
Genotype
URDs (n 5 138) Sibling (n 5 102)
Donor Type Recipient Type Donor Type Recipient Type
aGVHD(%) P Value aGVHD(%) P Value aGVHD(%) P Value aGVHD(%) P Value
IVS7 +125 (rs2278293)
A/A 57.1 .178 65.0 .797 23.5 1.0 28.6 .735
G/A+G/G 70.9 68.6 23.5 22.7
IVS82106 (rs2278294)
G/G 65.1 .694 83.3 .048 28.0 .591 47.6 .008
G/A+A/A 69.5 63.9 22.1 17.3
Exon15 1572 (rs2228075)
A/A 58.3 .336 66.7 .910 18.8 .757 30.8 .498
G/A+G/G 69.9 68.3 24.4 22.5
50 flanking intron-exon region (rs714510)
C/C 66.7 .705 67.5 .869 24.6 .811 21.3 .635
C/T+T/T 70.2 68.9 21.6 26.8
aGVHD indicates acute graft-versus-host disease; URDs, unrelated donors. P-values <.05 are given in bold font.
Biol Blood Marrow Transplant 18:273-279, 2012 277IMPDH1 Gene Polymorphisms and aGVHDdeveloping aGVHD (relative risk [RR] 5 2.018, 95%
confidence interval [CI]: 1.354-3.009, P 5 .001). Other
variables associated with the risk of aGVHD were
myeloablative conditioning (RR 5 3.309, 95% CI:
1.538-7.121, P 5 .002), female donor/male recipient
(RR 5 1.679, 95% CI: 1.139-2.475, P 5 .009), and
URD (RR 5 4.633, 95% CI: 2.934-7.315, P\ .001).
All 4 variables also contributed significantly to the
development of grades II-IV aGVHD (P\ .05).DISCUSSION
The results of the present study confirmed the find-
ings of previous studies suggesting that URD, myeloa-
blative conditioning, and female donor/male recipient
are risk factors for developing aGVHD. However, it
is now appreciated that the initiation and propagation
of GVHD is a multifactorial, multistep process that in-
cludes, but is not restricted to, classic HLA allorecog-
nition [29]. In our previous studies, we reported the
relationship between polymorphisms in donor and/or
recipient cytokine genes, such as tumor necrosis factorTable 5. Multivariate Analysis of Risk Factors for aGVHD and Grad
Variable RR (9
Donor-recipient gender Female to male 1.679 (1.
Others
Conditioning regimen Myeloablative therapy 3.309 (1.
RIC
Donor type URDs
HLA matched sibling
4.633 (2.
Transplant material Bone marrow 1.015 (0.
PBSC
HLA matching Allele matched 1.106 (0.
1or 2 allele mismatched
Recipient IVS8 -106 genotype G/G 2.018 (1.
Others
PBSC indicates peripheral blood stem cell; URDs, unrelated donors; CI, confid
RIC, reduced-intensity conditioning. P-values <.05 are given in bold font.(TNF)-a, TNF-b, transforming growth factor-b and
interleukin-10, and the risk of aGVHD in allo-
HSCT [30,31]. An increasing number of studies have
suggested that genetic variations in metabolizing
enzymes, transporters, and targets of drugs frequently
used in allo-HST, including cytochrome P450 2B6
(CYP2B6) and methylenetetrahydrofolate reductase,
can also influence HSCT outcomes [3,32,33].
Yatscoff et al. [34] found no inhibition of IMPDH
activity in some renal transplant patients with rejec-
tion, despite apparently adequate MPA concentra-
tions. The significant interindividual variability in
the effects of a given concentration of MPA indicates
that IMPDH expression is associated with MPA effi-
cacy. The genes encoding IMPDH1 and IMPDH2
are located on 2 different chromosomes. IMPDH1 is
located on chromosome 7 region q32.1, and its ex-
pression is reportedly more variable than that of
IMPDH2, which may be attributed to the presence
of 3 promoters within the IMPDH1 gene [35]. A re-
cent study conducted in renal transplant patients dem-
onstrated an association between 2 intronic IMPDH1
SNPs (IVS7 1125 G.A, rs2278293; IVS82106es II-IV aGVHD
aGVHD Grades II-IV aGVHD
5%CI) P Value RR (95% CI) P Value
139-2.475) .009 1.890 (1.158-3.084) .011
538-7.121) .002 4.782 (1.501-15.238) .008
934-7.315) <.001 5.591 (3.031-10.315) <.001
687-1.501) .940 0.740 (0.445-1.231) .246
723-1.692) .643 1.413 (0.843-2.369) .189
354-3.009) .001 2.232 (1.352-3.685) .002
ence interval; RR, relative risk; aGVHD, acute graft-versus-host disease;
278 Biol Blood Marrow Transplant 18:273-279, 2012W. Cao et al.G.A, rs2278294) and the incidence of biopsy-proven
acute rejection; patients with the IMPDH1 IVS82106
G/G genotype had a higher incidence of acute renal
rejection [14]. The present study also found a higher
incidence of aGVHD in recipients with the IMPDH1
IVS82106 G/G genotype among those with HLA-
identical sibling donors, as well as in those with
URDs, although the incidence of aGVHD was sig-
nificantly different between 2 cohorts. Multivariate
analysis confirmed that IMPDH1 IVS82106 G/G re-
cipients were at increased risk of developing aGVHD
and grades II-IV aGVHD. Although the exact influ-
ence of this polymorphism on the expression and func-
tion of IMPDH1 is not fully understood, intronic
polymorphisms generally seem to be associated with
the susceptibility and stability of mRNA. We specu-
lated that this polymorphism alone, or linkage to other
SNPs, may contribute to the regulation of IMPDH1
mRNA expression, enzyme activity, and ultimately to
MMF immunosuppressive efficacy.
Interestingly, this study found that only the recip-
ient’s IMPDH1 IVS82106 polymorphism status, and
not that of the donor, had a significant influence on
aGVHD. One possible explanation for this is that
the initiation of primary alloimmune responses in
allo-HSCT is known to result from the interaction
of recipient antigen-presenting cells (APCs), especially
recipient dendritic cells (DCs) and donor T lympho-
cytes. IMPDH1 is widely expressed, and preferentially
expressed in monocytes, rather than in lymphocytes
[36], and recipient APCs thus primarily express
IMPDH1, whereas donor T lymphocytes mainly
express IMPDH2. MMF has been shown to suppress
the proliferation of immature and mature DCs
in vitro, as a result of a decline of IMPDH1 activity,
and to also reduce their capacity to stimulate the pro-
liferation of T cells [36]. However, although IMPDH1
expression changes during immunosuppressive ther-
apy, the expression of IMPDH2 remains more stable
[37], and the association between the recipient’s
IMPDH1 polymorphism and aGVHD may thus be-
come more apparent. We failed to detect any associa-
tion between other IMPDH1 gene SNPs and the
development of aGVHD, or between IMPDH1 gene
polymorphisms and cGVHD, relapse, or OS. This
could be because patients received low-dose, short-
term MMF for GVHD prophylaxis to reduce
MMF’s side effects, as well as other comedications,
such as calcineurin inhibitors, which could reduce
the influence of IMPDH1 gene polymorphisms on
GVHD. Numerous factors could affect the relapse
and OS rates and may precede the influence of phar-
macogenetic polymorphisms.
Both pharmacogenetic and immunogenetic vari-
abilities could potentially affect the transplant immune
response, and transplant patients would thus benefit
from individualization of immunosuppressive therapy,taking into account donor and recipient genetic data,
as well as other risk factors. MMF is widely used clin-
ically to prevent and treat GVHD in allo-HSCT;
however, it is frequently administered to transplant pa-
tients without monitoringMPA plasma concentration,
IMPDH activity, or other relevant gene polymor-
phisms. This study is the first to report the relationship
between IMPDH1 gene polymorphisms and the risk
of aGVHD in allo-HSCT. The results may provide
useful information for the accurate assessment of
MMF-treated patients who are at risk of developing
aGVHD, and to aid in the selection of appropriate
immunosuppressive therapy.ACKNOWLEDGMENTS
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